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Abstract
Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy are candi-
dates for palliation with hypoxic pelvic perfusion (HPP). The aim of this observational retrospective study was to evaluate 
if a multimodality treatment including HPP and targeted-therapy may be useful to prolong clinical responses and survival 
of these patients. From a cohort of 77 patients with unresectable recurrent rectal cancer in progression after standard treat-
ments and submitted to HPP, 21 patients underwent repeat HPP using mitomycin C (MMC) at the dose of 25 mg/m2. After 
the last HPP, 7 patients received a targeted-therapy with cetuximab according to overexpression of epidermal growth factor 
receptor in recurrence cancer cells. The median overall survival of these 21 patients from the diagnosis of unresectable 
recurrent rectal cancer was 23 months (iqr 18–24). After the first HPP, the median survival of the 21 patients until death 
or end of follow-up was 10 months (iqr 9–13). The 1-year and 2-year survival rates were 71.4%, and 4.8%, respectively. 
From the first HPP, age > 60 years, a recurrence shrinkage of at least 30% (partial response), and the addition of a post-HPP 
targeted-therapy with cetuximab significantly affected survival (P < 0.04). In conclusion, repeated MMC-HPP followed by 
targeted-therapy seems to be an effective palliative treatment for patients with unresectable recurrent rectal cancer in progres-
sion after systemic chemotherapy and radiation but the results of this study have to be confirmed by a larger phase III trial.
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Introduction
The incidence of rectal cancer local recurrences after 
curative intent surgery varies between 2.4 and 10% in 
modern series [1]. The management of locally recurrent 
rectal cancer in high volume specialist centers is based on 
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multidisciplinary modalities including extensive surgery, 
intraoperative and/or external irradiation, neoadjuvant 
and/or adjuvant systemic chemotherapy but, unfortunately, 
30–50% of patients are unresectable [2] and several types of 
palliation are adopted [3]. Hypoxic pelvic perfusion (HPP) 
is a type of chemotherapy palliation based on the isola-
tion of the pelvic circulation by blocking the blood flow in 
the aorta and the inferior vena cava with balloon catheters 
and at the level of the thigh with pneumatic cuffs [4]. The 
rationale of this loco-regional chemotherapy is based on the 
high tumor drug exposure in the perfused compartment and 
in the use of chemotherapeutic agents such as mitomycin 
C (MMC) who is 10 times more toxic to tumor cells under 
hypoxic conditions [5]. A median progression-free survival 
time of 6 months was reported at the beginning of the 2000s 
after one course of MMC HPP in patients with unresectable 
recurrent rectal cancer that had progressed after chemo-
radiotherapy [6]. HPP can be performed using a surgical or 
a percutaneous approach. A recent pharmacokinetic study 
demonstrated that the percutaneous approach is not signifi-
cantly different from the surgical one in terms of tumor drug 
exposure when MMC at the dose of 25 mg/m2 is adminis-
tered; consequently, when perfusion must be repeated sev-
eral times in the same patient, the percutaneous and surgical 
methods may be interchangeably adopted [7].
Based on the hypothesis that a multimodality treatment 
including HPP may be useful to prolong clinical responses 
and survival, a retrospective study has been done on a 
cohort of patients with unresectable recurrent rectal can-




Patients eligibility criteria were as follows: (i) diagnosis 
of unresectable recurrent rectal cancer; pelvic sidewall 
involvement, growth into the sciatic notch, involvement 
of the first and/or second sacral vertebra, and/or encase-
ment of the bladder or iliac vessels were the main criteria 
for unresectability, (ii) apparent increase of recurrence size 
for at least 3 months after radiation therapy or systemic 
chemotherapy, (iii) performance status of 0–3 based on the 
Eastern Cooperative Oncology Group (ECOG), (iv) leu-
kocyte count > 2500 cells/mm3 and platelet count > 50,000 
cells/mm3, (v) serum creatinine concentration ≤ 1.2 mg/
dL, (vi) subjects with liver failure, deep venous throm-
bosis, severe atherosclerosis, or coagulopathy were not 
eligible.
Patients characteristics
This retrospective observational study was performed at 
the University of L’Aquila, L’Aquila, Italy, after approval 
from the investigational review board (n.10/CE/2018) and 
following the consideration that the patients had an unre-
sectable disease with a predictable course outcome. In a 
cohort of 77 patients with unresectable recurrent rectal 
cancer in progression after radiotherapy and/or systemic 
chemotherapy and submitted to HPP, 21 patients under-
went repeat HPP using MMC at the dose of 25 mg/m2, 
from 2001 to 2017; 56 patients were excluded from this 
study because they were submitted to HPP using different 
drugs schedule. Written consent was obtained after they 
were given complete information about the disease and 
the implications of the proposed palliative treatment, in 
accordance with the ethical standards of the committee on 
human experimentation at our institution. Table 1 shows 
Table 1  Characteristics of 21 patients with unresectable recurrent 
rectal cancer in progression after standard treatments





Age Mean ± S.D. (years)
64.13 ± 13.98
Median Iqr (months)
Median elapse time from diagnosis of 





 Endovenous systemic chemotherapy 21 100.0
  ≥ 3 Systemic chemotherapy lines 17 81.0
  < 3 Systemic chemotherapy lines 4 19.0
 Radiotherapy 21 100.0
  Re-irradiation 18 85.7
  Radiation before diagnosis of unre-








EGFR overexpression N %
 Yes 7 33.3
 Not 14 66.7
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demographic data. The median elapse time from the diag-
nosis of unresectable recurrent rectal cancer to the first 
MMC-HPP was 10 months (iqr 9–14).
Perfusions were repeated at intervals of approximately 
8 weeks. The rationale and timing of repetition in patients 
obtaining partial response or stable disease were based on 
a previous pilot study [6] showing that progression was 
always observed in presence of residual tumor. In case of 
complete response, the treatment was not repeated. Treat-
ments were not repeated if the patient did not consent, 
local recurrence progressed more than 20% in dimension, 
simultaneous distant relapses occurred, or the general con-
dition of the patient worsened.
HPP techniques and MMC regimen
Before undergoing perfusion, patients received an angiog-
raphy, or angio-CT, of the aorto-iliac tree and the inferior 
vena cava. Perfusions were performed under general anes-
thesia, using surgical or percutaneous approach as pre-
viously published [7]. When perfusion must be repeated 
more than 2 or 3 times in the same patient and the femoral 
vessels were surrounded by fibrous tissue, the surgical 
method could be done with iliac vessels exposure but the 
percutaneous puncture of femoral vessels is also feasi-
ble. Figure 1 shows a schema of the techniques.
MMC (25 mg/m2), diluted in 250 mL of an isotonic 
sodium chloride solution containing 16 mg of dexametha-
sone sodium phosphate, was administered over a 3-min 
period at the beginning of HPP. Chemofiltration was 
always administered for 60 min at the end of HPP.
Post‑HPP therapies
After the last HPP, 7 patients received a targeted-ther-
apy with cetuximab at the dose of 250 mg/m2 according 
to overexpression of epidermal growth factor receptor 
(EGFR) in recurrence cancer cells.
Criteria for responses and adverse events
Tumor responses were assessed using the Response Evalu-
ation Criteria in Solid Tumors, version 1.1 [8] 30–45 days 
after each loco-regional chemotherapy treatment. Responses 
of patients treated before 2009 were retrospectively re-clas-
sified. Computed tomography (CT), Magnetic Resonance 
Imaging (MRI), and Positron-emission Tomography (PET) 
were used to evaluate responses. Pelvic pain requiring at 
least less than 50% of preoperative analgesic administra-
tion 30 days after perfusion was considered an objective 
pain relief. Adverse events were assessed by using Common 
Fig. 1  Schema of the surgical and percutaneous (in cartouche) hypoxic pelvic perfusions with chemofiltration
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Terminology Criteria for Adverse Events of the National 
Cancer Institute (CTCAE v4.03).
Statistical analysis
Descriptive statistics estimated with 95% confidence were 
provided. The means ± the standard deviation (SD) have 
been calculated. Survival was estimated by using the 
Kaplan–Meier product limit estimator. No patients were lost 
to follow-up. Survival times were stratified according to the 
clinical variables that can potentially affect survival. Log-
rank tests were used to assess the significance of the differ-
ences between the groups. Hazard ratios were estimated by 
using a proportional hazard Cox regression model. Progres-
sion-free survival time (PFS) was calculated from the day 
of the first locoregional treatment. Statistical analysis was 
performed using STATA software, version 14 (StataCorp, 
College Station, Texas).
Results
The 21 patients underwent 44 HPP, 28 with the surgical 
approach, 16 with the percutaneous procedure. The mean 
HPP number per patient was 2.1 ± 0.1 (median, 2 perfu-
sions). The length of hospital stay after the surgical pro-
cedure (mean, 10.2 ± 5.5 days) was significantly longer 
(P = 0.01; Mann–Whitney test) than that after percutane-
ous procedure (mean, 5.3 ± 2.7 days). This difference was 
due to iliac vessel exposures and to lymphadenectomies 
that were performed only in patients submitted to surgical 
procedure.
Tolerability and procedure‑related complications
There were no technical, hemodynamic, or vascular compli-
cations during the 44 perfusions, and no perfusion-related 
postoperative deaths. Femoral cannulation was always pos-
sible. The cardiac evaluation with electrocardiography and 
echocardiography did not show any significant variation 
before and after perfusions. The complications registered in 
patients receiving the surgical procedure (which was associ-
ated with lymphadenectomy in 3 patients) were seroma (2 
patients), persistent leakage of lymphatic fluid from incision 
(5 patients), and wound infection (1 patients). One patient 
receiving the percutaneous procedure had an inguinal hema-
toma (Table 2).
HPP with chemofiltration‑related toxicity
Perfusion-related hematological toxicity was not relevant 
(Table  2). Among the 44 perfusions, the number (per-
centage) of grade 1, grade 2, and grade 3 toxicities was 5 
(23.8%), 2 (9.5%), and 1 (4.7%), respectively. Patients with 
neutropenia received supportive therapy consisting of gran-
ulocyte colony-stimulating factor. Hematological toxicity 
stopped treatment in one (4.7%) patient. Two cases of grade 
2 alopecia were registered, and grade 1–2 gastrointestinal 
toxicity was observed in 5 patients. Local toxicity, mainly 
manifesting as scrotum edema and pain, was registered in 
2 patients.
Tumor and pain responses
The overall response rate after the first treatment was 38% 
with exclusively partial responses. 13 patients had stable dis-
ease (62%). There was no disease progression in the 30 days 
after the first treatment. No partial responses have been reg-
istered in the HPP courses following the first. Ten patients 
with pelvic pain showed a considerable decrease in pain and 
analgesic requirement within 36–48 h of the first treatment. 
Partial relief of pain was registered 1 month after HPP in 
4 patients. In 10 patients a moderate improvement of the 
general conditions has been registered a month later HPP.
Survival
The median overall survival of these 21 patients from 
the diagnosis of unresectable recurrent rectal cancer was 
23 months (iqr 18–24). All these patients underwent sys-
temic chemotherapy, radiotherapy and surgery for the 
treatment of recurrence with a median elapse time from 
the recurrence diagnosis to the first HPP of 10 months (iqr 
9–14). After the first HPP, the median survival of the 21 
patients until death or end of follow-up was 10 months (iqr 
Table 2  Procedure related complications and toxicity after 44 HPP in 
21 patients with unresectable recurrent rectal cancer in progression 
after systemic chemotherapy and radiotherapy
n  numbers of cases
Grade n (%)
Complications
Seroma 1 2 (9.5)
Persistent leakage of fluid from the 
incision
2 5 (23.8)
Wound infection 1 1 (4.7)
Inguinal hematoma 1 1 (4.7)
Scrotum edema 1 2 (9.5)
Pelvic pain 1 4 (19)
Toxicity
Bone marrow hypocellularity 1 5 (23.8)
2 2 (9.5)
3 1 (4.7)
Alopecia 2 2 (9.5)
Nausea and vomiting 1 5 (23.8)
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9–13). The 1-year and 2-year survival rates were 71.4%, and 
4.8%, respectively.
From the first HPP, age > 60 years, a recurrence shrink-
age of at least 30% (partial response), and the addition of 
a post-HPP targeted-therapy affected survival (Fig. 2a–c), 
whereas gender, number of HPP and the presence of other 
sites of metastases did not. The MST was 14 months (mean, 
14 ± 6.7 months) for patients aged more than 60 years and 
10 months (mean, 9.7 ± 3.6 months) for patients younger 
than 60 years [χ2 = 7.34, P = 0.007, Cox hazard ratio = 5.79]. 
The median survival time (MST) of the patients who experi-
enced a partial response after HPP treatments was 12 months 
(mean, 12.5 ± 5.5 months), at the contrary if the patients 
had a stable disease, the MST was 10  months (mean, 
9.6 ± 3.9 months) [χ2 = 4.1 in the log-rank test, P = 0.04, 
Cox hazard ratio = 2.63]. The MSTs of the patients who 
received a targeted-therapy after the last HPP was 13 months 
(mean, 14.3 ± 5.4); without post-HPP therapy the MST was 
10 months (mean, 8.9 ± 3.2) [χ2 = 5.42, P = 0.02, Cox hazard 
ratio = 3.27].
In the 21 patients, a median value of 6 months (iqr 5–7) 
for PFS has been calculated from the first HPP. A shrinkage 
of at least 30% (partial response) of the recurrent cancer, sig-
nificantly influenced the PFS, whereas gender, age, number 
of HPP and the presence of other sites of metastases did not. 
The PFS of the patients who experienced a partial response 
after HPP treatments was 7 months (mean, 9.1 ± 5.3 months), 
at the contrary if the patients had a stable disease, the PFS 
was 6 months (mean, 5.6 ± 1.9 months) [χ2 = 6.3 in the log-
rank test, P = 0.01, Cox hazard ratio = 3.87] (Table 3).
Follow‑up
In 7 patients, targeted-therapy with cetuximab at the dose 
of 250 mg/m2 was administered after the last HPP, with 
grade 2 dermatological toxicity in 3 patients. Among the 
21 patients, 3 (14.28%) patients were alive at the end of 
follow-up, and 18 (85.71%) patients were dead because of 
relapse of rectal cancer. Interruptions after the first HPP 
treatment were due to refused consent in 6 cases and in 1 
case for hematological toxicity. In 10 patients (47.61%) 
interruption of HPP treatments was due to disease pro-
gression, in 4 patients (19.04%) was due to worsening of 
general conditions. Site of progression was both distant 
and local in 20 patients (95.23%).
Discussion
As for other sites of rectal cancer relapse [9], the manage-
ment of recurrent rectal cancer requires a multidisciplinary 
approach. When patients with locally unresectable recur-
rent rectal cancer were treated exclusively with radiotherapy, 
MST of 12 months was reported for palliative re-irradiation 
at the end of 1990s [10], but a similar median survival of 
13 months has been very recently reported without apparent 
improvement of the therapeutic efficacy [11]. Our retrospec-
tive study on patients with unresectable recurrent rectal can-
cer that had progressed following radiotherapy and/or sys-
temic chemotherapy demonstrated that a multidisciplinary 
treatment including repeated courses of MMC-HPP provides 
further MST of 10 months. When MMC-HPP is followed 
by targeted-therapy, the MST growth up to 13 months; in 
this sub-group of patients the overall median survival from 
the diagnosis of unresectable recurrent rectal cancer was 
24 months (mean, 26.2 ± 7.2 months).
A survival ranging from 10 to 18 months have been previ-
ously reported after a single course of HPP in patients with 
unresectable recurrent rectal cancer that had progressed fol-
lowing radiotherapy or systemic chemotherapy [3, 6, 12, 13]. 
When HPP was routinely performed twice, a mean survival 
time of 24 months was reported in a Japanese study, adopt-
ing a drugs schedule with cisplatin (high dose escalated from 
A B C
Fig. 2  Survival in 21 patients with unresectable recurrent rectal can-
cer in progression after systemic chemotherapy and radiotherapy sub-
mitted to repeated courses of MMC HPP. Stratification according to 
age lower or higher than 60 years (a), type of response (b), and post-
HPP therapy (c)
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170 mg/m2) and 5-fluorouracil (fixed dose of 1000 mg/m2) 
[14]. This seems to support the hypothesis that repeated 
perfusions may be useful to prolong clinical responses and 
survival. In our study, using MMC monotherapy at the dose 
of 25 mg/m2 in repeated courses of HPP, the mean survival 
time was 11.4 months. It was to be considered that the unre-
sectable rectal cancer recurrences of the 21 patients included 
in this study had been heavily pre-treated with more than 
2 lines of systemic chemotherapy plus re-irradiation for a 
mean of 11 months; moreover, 16 of 21 patients had distant 
metastases. This suggest that lack of patient homogeneity 
makes it difficult to compare retrospective observational 
studies. However, in our study, the MST of patients submit-
ted to 1 HPP (10 months, iqr 5–13) was not significantly 
lower than that of patients who underwent 2 or more HPP 
(10.5 months, iqr 9–14). More than the repetition in self, 
the different chemotherapeutic schedule (platinum-based 
polychemotherapy versus MMC monotherapy) and dosage 
seem to play a relevant role in improving median survivals.
The most relevant aspect of this study was that a post-HPP 
targeted therapy have significantly improved the MST, sug-
gesting an important role for the biomolecular characteristics 
of the recurrent cancer cells. The overexpression of EGFR 
has been utilized in these 21 patients to choose the targeted-
therapy but recent observations suggest that also mutations 
in the family of RAF (Rapidly Accelerated Fibrosarcoma) 
kinases and human epidermal growth factor receptor 2 
(HER2) amplifications should be always considered in colo-
rectal cancer relapse targeted-therapy [9]. Biomolecular 
aspects, such as microsatellite instability, could explain the 
significantly higher survival registered in patients over than 
60 years treated with a DNA-alkylating agent (MMC) of this 
series in comparison to those younger than 60 years.
As concerning tolerability of locoregional chemotherapy 
in terms of cytotoxic side-effects, this study confirms previ-
ously reported data [14, 15] about the efficacy of detoxifying 
treatments, such as chemofiltration or dialysis. Using che-
mofiltration after HPP, only 4.7% of treated patients expe-
rienced a G3 hematological toxicity. Moreover, a slow-flow 
HPP was adopted to reduce leakage and therefore to lower 
systemic toxicity because of a well-documented relationship 
[16] between the flow in the circuit and drug leakage to the 
systemic circulation.
A potential limitation of this study is that this is a phase 
II trial, and results must to be confirmed by a larger phase III 
study comparing different associations between locoregional 
chemotherapy and targeted-therapies.
Conclusions
In conclusion, MMC HPP seems to be an effective pallia-
tive treatment for patients with unresectable recurrent rec-
tal cancer in progression after systemic chemotherapy and 
Table 3  Survival in 21 patients 
with unresectable recurrent 
rectal cancer in progression 
after systemic chemotherapy 
and radiotherapy submitted to 
repeated courses of MMC HPP
Stratification according to age, gender, other sites of metastases stage, type of response, number of treat-
ments, post-HPP therapy
MST  median survival time, HR hazard ratio, ns not significant, PR partial response, SD stable disease
Variables (number of 
patients)
MST (months) Log-rank χ2 P value Cox HR
Age
 < 60 (n = 16) 10
 ≥ 60 (n = 5) 14 7.34 0.007 [5.79, 1.26–26.6]
Gender
 Female (n = 10) 10
 Male (n = 11) 10 0.06 (ns) 0.807
Other sites of metastases
 Yes (n = 16) 10
 Not (n = 5) 10 0.01 (ns) 0.936
Type of response
 PR (n = 8) 12
 SD (n = 13) 10 4.10 0.041 [2.63, 0.91–7.56]
Number of HPP treatments
 1 (n = 7) 10
 ≥ 2 (n = 14) 10.5 0.74 (ns) 0.390
Post-HPP therapy
 Not (n = 14) 19
 Yes (n = 7) 24 4.88 0.027 [3.27, 1.03–10.31]
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radiation. This palliative treatment rapidly reduced symp-
toms in patients with pelvic pain and improved general con-
ditions in a month; the symptoms response is a strong benefit 
in the palliative treatment of patients excluded from curative 
therapy. MMC HPP should be considered as a link of a chain 
in a multidisciplinary treatment based on recent observations 
of translational research.
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